Lupin's Ankleshwar Facility Receives US FDA EIR

Global pharma major Lupin Limited announced it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India. This positive outcome follows the closure of a product-specific Pre-Approval Inspection conducted from March 2 to March 7, 2026. Nilesh Gupta, Managing Director, stated that this reflects Lupin's ongoing commitment to quality excellence and regulatory compliance, reinforcing its ability to deliver safe and effective medicines globally.